Miltenyi Biotec
Miltenyi Biotec, a leading global biotechnology company headquartered in Germany (DE), has been at the forefront of innovative cell and gene therapy solutions since its founding in 1989. With a strong presence in Europe, North America, and Asia, the company focuses on developing advanced technologies for biomedical research and clinical applications. Specialising in cell separation, cell culture, and gene editing, Miltenyi Biotec offers unique products such as the MACS® Technology and the CliniMACS® Prodigy system, which streamline workflows and enhance research outcomes. Renowned for its commitment to quality and innovation, the company has achieved significant milestones, including the development of cutting-edge tools that support personalised medicine. Miltenyi Biotec's dedication to advancing scientific knowledge has solidified its position as a trusted partner in the life sciences industry, making it a key player in the ongoing evolution of therapeutic solutions.
DitchCarbon Score
How does Miltenyi Biotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Miltenyi Biotec's score of 25 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Miltenyi Biotec's reported carbon emissions
Miltenyi Biotec, headquartered in Germany, has made significant commitments towards achieving net-zero carbon emissions across all scopes by 2050. Although specific emissions data for the most recent year is not available, the company has established a long-term target to reduce its carbon footprint, aligning with the Science Based Targets initiative (SBTi). Miltenyi Biotec's commitment to net-zero emissions reflects its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company has been proactive in setting these targets since 2023, indicating a strategic approach to climate action. As part of its climate strategy, Miltenyi Biotec is focused on reducing emissions across all scopes, which includes direct emissions (Scope 1), indirect emissions from purchased energy (Scope 2), and other indirect emissions (Scope 3). This comprehensive approach underscores the company's recognition of the broader impact of its operations on climate change. While specific reduction percentages have not been disclosed, Miltenyi Biotec's commitment to net-zero by 2050 positions it as a responsible leader in the industry, aiming to contribute positively to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Miltenyi Biotec is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
